From arthritis to erectile dysfunction: potential pathophysiological mechanisms and multidisciplinary integrated management
Abstract
This review systematically examines the underlying mechanisms linking erectile dysfunction (ED) with arthritis and explores multidisciplinary management strategies. Epidemiological studies confirm that patients with various arthritis-including osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and gouty arthritis-exhibit significantly higher ED prevalence and incidence risks compared to the general population. This association remains independent of confounding factors such as age and comorbidities. Core mechanisms linking the two include chronic inflammation disrupting the "NO-cGMP-PKG" erectile molecular axis, vascular endothelial dysfunction causing insufficient penile blood supply, endocrine-metabolic disorders (e.g., insulin resistance, reduced testosterone), neuropsychological factors (anxiety, depression, chronic pain), and the synergistic effects of therapeutic agents (methotrexate, nonsteroidal anti-inflammatory drugs, glucocorticoids). Clinical recommendations advocate an "active screening-tiered assessment" approach, utilizing the International Index of Erectile Function (IIEF) combined with disease activity tools (e.g., DAS28, BASDAI) for screening and evaluation. Management should follow a multidisciplinary team (MDT) model integrating "control of underlying disease + individualized ED treatment + psychological intervention + lifestyle optimization" to improve patients' overall health outcomes ultimately.
Read the paper
Related studies
- Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling
- Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
- Luteolin Inhibits Dexamethasone‐Induced Osteoporosis by Autophagy Activation Through miR‐125b‐5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
- Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
- Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.